PURPOSE: Although prostate-specific antigen (PSA) is the best biomarker for predicting prostate cancer, its predictive performance needs to be improved. Results from the Prostate Cancer Prevention Trial revealed the overall performance measured by the areas under curve of the receiver operating characteristic at 0.68. The goal of the present study is to assess the ability of genetic variants as a PSA-independent method to predict prostate cancer risk. EXPERIMENTAL DESIGN: We systematically evaluated all prostate cancer risk variants that were identified from genome-wide association studies during the past year in a large population-based prostate cancer case-control study population in Sweden, including 2,893 prostate cancer patients and 1,781 men without prostate cancer. RESULTS: Twelve single nucleotide polymorphisms were independently associated with prostate cancer risk in this Swedish study population. Using a cutoff of any 11 risk alleles or family history, the sensitivity and specificity for predicting prostate cancer were 0.25 and 0.86, respectively. The overall predictive performance of prostate cancer using genetic variants, family history, and age, measured by areas under curve was 0.65 (95% confidence interval, 0.63-0.66), significantly improved over that of family history and age (0.61%; 95% confidence interval, 0.59-0.62; P = 2.3 x 10(-10)). CONCLUSION: The predictive performance for prostate cancer using genetic variants and family history is similar to that of PSA. The utility of genetic testing, alone and in combination with PSA levels, should be evaluated in large studies such as the European Randomized Study for Prostate Cancer trial and Prostate Cancer Prevention Trial.
PURPOSE: Although prostate-specific antigen (PSA) is the best biomarker for predicting prostate cancer, its predictive performance needs to be improved. Results from the Prostate Cancer Prevention Trial revealed the overall performance measured by the areas under curve of the receiver operating characteristic at 0.68. The goal of the present study is to assess the ability of genetic variants as a PSA-independent method to predict prostate cancer risk. EXPERIMENTAL DESIGN: We systematically evaluated all prostate cancer risk variants that were identified from genome-wide association studies during the past year in a large population-based prostate cancer case-control study population in Sweden, including 2,893 prostate cancerpatients and 1,781 men without prostate cancer. RESULTS: Twelve single nucleotide polymorphisms were independently associated with prostate cancer risk in this Swedish study population. Using a cutoff of any 11 risk alleles or family history, the sensitivity and specificity for predicting prostate cancer were 0.25 and 0.86, respectively. The overall predictive performance of prostate cancer using genetic variants, family history, and age, measured by areas under curve was 0.65 (95% confidence interval, 0.63-0.66), significantly improved over that of family history and age (0.61%; 95% confidence interval, 0.59-0.62; P = 2.3 x 10(-10)). CONCLUSION: The predictive performance for prostate cancer using genetic variants and family history is similar to that of PSA. The utility of genetic testing, alone and in combination with PSA levels, should be evaluated in large studies such as the European Randomized Study for Prostate Cancer trial and Prostate Cancer Prevention Trial.
Authors: Julius Gudmundsson; Patrick Sulem; Thorunn Rafnar; Jon T Bergthorsson; Andrei Manolescu; Daniel Gudbjartsson; Bjarni A Agnarsson; Asgeir Sigurdsson; Kristrun R Benediktsdottir; Thorarinn Blondal; Margret Jakobsdottir; Simon N Stacey; Jelena Kostic; Kari T Kristinsson; Birgitta Birgisdottir; Shyamali Ghosh; Droplaug N Magnusdottir; Steinunn Thorlacius; Gudmar Thorleifsson; S Lilly Zheng; Jielin Sun; Bao-Li Chang; J Bradford Elmore; Joan P Breyer; Kate M McReynolds; Kevin M Bradley; Brian L Yaspan; Fredrik Wiklund; Par Stattin; Sara Lindström; Hans-Olov Adami; Shannon K McDonnell; Daniel J Schaid; Julie M Cunningham; Liang Wang; James R Cerhan; Jennifer L St Sauver; Sara D Isaacs; Kathleen E Wiley; Alan W Partin; Patrick C Walsh; Sonia Polo; Manuel Ruiz-Echarri; Sebastian Navarrete; Fernando Fuertes; Berta Saez; Javier Godino; Philip C Weijerman; Dorine W Swinkels; Katja K Aben; J Alfred Witjes; Brian K Suarez; Brian T Helfand; Michael L Frigge; Kristleifur Kristjansson; Carole Ober; Eirikur Jonsson; Gudmundur V Einarsson; Jianfeng Xu; Henrik Gronberg; Jeffrey R Smith; Stephen N Thibodeau; William B Isaacs; William J Catalona; Jose I Mayordomo; Lambertus A Kiemeney; Rosa B Barkardottir; Jeffrey R Gulcher; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson Journal: Nat Genet Date: 2008-02-10 Impact factor: 38.330
Authors: Jacques B de Kok; Gerald W Verhaegh; Rian W Roelofs; Daphne Hessels; Lambertus A Kiemeney; Tilly W Aalders; Dorine W Swinkels; Jack A Schalken Journal: Cancer Res Date: 2002-05-01 Impact factor: 12.701
Authors: David Duggan; Siqun L Zheng; Michele Knowlton; Debbie Benitez; Latchezar Dimitrov; Fredrik Wiklund; Christiane Robbins; Sarah D Isaacs; Yu Cheng; Ge Li; Jielin Sun; Bao-Li Chang; Leslie Marovich; Kathleen E Wiley; Katarina Bälter; Pär Stattin; Hans-Olov Adami; Marta Gielzak; Guifang Yan; Jurga Sauvageot; Wennuan Liu; Jin Woo Kim; Eugene R Bleecker; Deborah A Meyers; Bruce J Trock; Alan W Partin; Patrick C Walsh; William B Isaacs; Henrik Grönberg; Jianfeng Xu; John D Carpten Journal: J Natl Cancer Inst Date: 2007-12-11 Impact factor: 13.506
Authors: Iona Cheng; Sarah J Plummer; Eric Jorgenson; Xin Liu; Benjamin A Rybicki; Graham Casey; John S Witte Journal: Eur J Hum Genet Date: 2008-01-30 Impact factor: 4.246
Authors: Jielin Sun; Lina Purcell; Zhengrong Gao; Sarah D Isaacs; Kathleen E Wiley; Fang-Chi Hsu; Wennuan Liu; David Duggan; John D Carpten; Henrik Grönberg; Jianfeng Xu; Bao-Li Chang; Alan W Partin; Patrick C Walsh; William B Isaacs; S Lilly Zheng Journal: Prostate Date: 2008-05-15 Impact factor: 4.104
Authors: Hannah K Weir; Michael J Thun; Benjamin F Hankey; Lynn A G Ries; Holly L Howe; Phyllis A Wingo; Ahmedin Jemal; Elizabeth Ward; Robert N Anderson; Brenda K Edwards Journal: J Natl Cancer Inst Date: 2003-09-03 Impact factor: 13.506
Authors: Rosalind A Eeles; Zsofia Kote-Jarai; Graham G Giles; Ali Amin Al Olama; Michelle Guy; Sarah K Jugurnauth; Shani Mulholland; Daniel A Leongamornlert; Stephen M Edwards; Jonathan Morrison; Helen I Field; Melissa C Southey; Gianluca Severi; Jenny L Donovan; Freddie C Hamdy; David P Dearnaley; Kenneth R Muir; Charmaine Smith; Melisa Bagnato; Audrey T Ardern-Jones; Amanda L Hall; Lynne T O'Brien; Beatrice N Gehr-Swain; Rosemary A Wilkinson; Angie Cox; Sarah Lewis; Paul M Brown; Sameer G Jhavar; Malgorzata Tymrakiewicz; Artitaya Lophatananon; Sarah L Bryant; Alan Horwich; Robert A Huddart; Vincent S Khoo; Christopher C Parker; Christopher J Woodhouse; Alan Thompson; Tim Christmas; Chris Ogden; Cyril Fisher; Charles Jamieson; Colin S Cooper; Dallas R English; John L Hopper; David E Neal; Douglas F Easton Journal: Nat Genet Date: 2008-02-10 Impact factor: 38.330
Authors: Gilles Thomas; Kevin B Jacobs; Meredith Yeager; Peter Kraft; Sholom Wacholder; Nick Orr; Kai Yu; Nilanjan Chatterjee; Robert Welch; Amy Hutchinson; Andrew Crenshaw; Geraldine Cancel-Tassin; Brian J Staats; Zhaoming Wang; Jesus Gonzalez-Bosquet; Jun Fang; Xiang Deng; Sonja I Berndt; Eugenia E Calle; Heather Spencer Feigelson; Michael J Thun; Carmen Rodriguez; Demetrius Albanes; Jarmo Virtamo; Stephanie Weinstein; Fredrick R Schumacher; Edward Giovannucci; Walter C Willett; Olivier Cussenot; Antoine Valeri; Gerald L Andriole; E David Crawford; Margaret Tucker; Daniela S Gerhard; Joseph F Fraumeni; Robert Hoover; Richard B Hayes; David J Hunter; Stephen J Chanock Journal: Nat Genet Date: 2008-02-10 Impact factor: 38.330
Authors: Mark M Pomerantz; Yashaswi Shrestha; Richard J Flavin; Meredith M Regan; Kathryn L Penney; Lorelei A Mucci; Meir J Stampfer; David J Hunter; Stephen J Chanock; Eric J Schafer; Jennifer A Chan; Josep Tabernero; José Baselga; Andrea L Richardson; Massimo Loda; William K Oh; Philip W Kantoff; William C Hahn; Matthew L Freedman Journal: PLoS Genet Date: 2010-11-11 Impact factor: 5.917
Authors: S Lilly Zheng; Victoria L Stevens; Fredrik Wiklund; Sarah D Isaacs; Jielin Sun; Shelly Smith; Kristen Pruett; Kathleen E Wiley; Seong-Tae Kim; Yi Zhu; Zheng Zhang; Fang-Chi Hsu; Aubrey R Turner; Jan-Erik Johansson; Wennuan Liu; Jin Woo Kim; Bao-Li Chang; David Duggan; John Carpten; Carmen Rodriguez; William Isaacs; Henrik Grönberg; Jianfeng Xu Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-06 Impact factor: 4.254
Authors: Bao-Li Chang; Scott D Cramer; Fredrik Wiklund; Sarah D Isaacs; Victoria L Stevens; Jielin Sun; Shelly Smith; Kristen Pruett; Lina M Romero; Kathleen E Wiley; Seong-Tae Kim; Yi Zhu; Zheng Zhang; Fang-Chi Hsu; Aubrey R Turner; Jan Adolfsson; Wennuan Liu; Jin Woo Kim; David Duggan; John Carpten; S Lilly Zheng; Carmen Rodriguez; William B Isaacs; Henrik Grönberg; Jianfeng Xu Journal: Hum Mol Genet Date: 2009-01-19 Impact factor: 6.150
Authors: Julian Little; Brenda Wilson; Ron Carter; Kate Walker; Pasqualina Santaguida; Eva Tomiak; Joseph Beyene; Muhammad Usman Ali; Parminder Raina Journal: Genet Med Date: 2015-10-01 Impact factor: 8.822